ClinicalTrials.gg
Drug

Binimetinib clinical trials

Also written MEK162, Mektovi and ARRY-438162.

studies test it
101
open now
11
in phase 3
7
first study started
2008

How each study uses binimetinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the binimetinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
27 Jun 2018 · MEKTOVI · NDA 210498 (FDA, Drugs@FDA)
European Union
20 Sept 2018 · Mektovi · EMEA/H/C/004579 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Binimetinib
64
Binimetinib 15 MG
3
MEK inhibitor MEK162
2
MEK inhibitor ARRY-438162
2
MEK162 or ARRY-438162
2

Brand

Mektovi
25

Development codes

MEK162
46
ARRY-438162
20
ARRY-162
19
PF-06811462
1
NSC 788187
1

In one entry with another drug

Given together, or one or the other

MEK162, MEK inhibitor; oral
2

Studies by the year they started

101 studies that test it; most in 2019 (11)

Studies that test binimetinib, by start year
YearStudies
20081
20091
20115
20125
201310
20146
20155
20169
20177
20186
201911
20209
202111
20225
20236
20244

By phase

A phase 1/2 study counts in both.

Early Phase 1
2
Phase 1
44
Phase 2
62
Phase 3
7
Phase 4
1
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 39 · Other 62

Pfizer (21) · Array Biopharma, now a wholly owned subsidiary of Pfizer (9) · National Cancer Institute (NCI) (8) · M.D. Anderson Cancer Center (5) · Pierre Fabre Medicament (5) · University Health Network, Toronto (4) · Memorial Sloan Kettering Cancer Center (4) · H. Lee Moffitt Cancer Center and Research Institute (3)

Often tested with

Tested in the same studies.

Encorafenib (38) · Nivolumab (8) · Palbociclib (7) · Pembrolizumab (6) · Dabrafenib (4) · Trametinib (4) · Ribociclib (4) · Alpelisib (3)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 9, 2 in phase 3

Studies that test binimetinib, phase 3 first.

Studies

Open first, then newest update. How each study uses binimetinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 101

See all 101 studies that test binimetinib →

Given beside what is tested · 16 — binimetinib is usual care or a partner of the new treatment

Codes

What other systems call binimetinib · ClinicalTrials.gg INT006287

  • MeSH (NLM) C581313binimetinibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 181R97MR71BINIMETINIBConfirmed FDA, NLM, Wikidata
  • RxNorm 2049122Confirmed FDA, Wikidata
  • Wikidata Q19903515binimetinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C84865BinimetinibOne source FDA
  • DrugBank DB11967One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.